16mon MSN
Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its ...
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
Eli Lilly And Co. LLY, a top pick for the firm, is projected to see continued growth in its diabetes and obesity ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad Money, recently ...
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback